Washington Examiner
Moderna and Pfizer are each in the process of competing for federal contracts to build a national stockpile of mRNA vaccines targeted toward the new bird flu amid mounting concerns it may be spreading among humans.
Sources familiar with the discussions between the pharmaceutical giants and the Department of Health and Human Services report that the agency may agree to fund Moderna’s late-stage clinical trials of the bird flu vaccine to the tune of tens of millions of dollars.
The H5N1 strain of bird flu, or the highly pathogenic avian influenza, has been a growing problem in North America since 2022, but the problem has substantially increased following the infection of cattle herds across nine states since March.
READ THE FULL STORY
